Mostrar el registro sencillo del ítem

dc.contributor.authorLopez-Lopez, P.*
dc.contributor.authorFrias, M.*
dc.contributor.authorPerez-Jimenez, A.B.*
dc.contributor.authorFreyre-Carrillo, C.*
dc.contributor.authorPineda, J.A.*
dc.contributor.authorAguilera Guirao, Antonio *
dc.contributor.authorFuentes, A.*
dc.contributor.authorAlados, J.C.*
dc.contributor.authorReina, G.*
dc.contributor.authorRamirez-Arellano, E.*
dc.contributor.authorViciana, I.*
dc.contributor.authorMesquita, J.*
dc.contributor.authorCaballero-Gomez, J.*
dc.contributor.authorRivero-Juarez, A.*
dc.contributor.authorRivero, A.*
dc.date.accessioned2025-09-12T11:47:54Z
dc.date.available2025-09-12T11:47:54Z
dc.date.issued2023
dc.identifier.citationLopez-Lopez P, Frias M, Perez-Jimenez AB, Freyre-Carrillo C, Pineda JA, Aguilera A, et al. Optimization of the molecular diagnosis of the acute hepatitis E virus infection. Microbial Biotechnology. 2023;16(6):1325-32.
dc.identifier.issn1751-7915
dc.identifier.otherhttps://portalcientifico.sergas.gal//documentos/6433d2afe8f2fa0e62f2b7e5
dc.identifier.urihttp://hdl.handle.net/20.500.11940/21812
dc.description.abstractTo evaluate the diagnostic value of the combination of two broad-range PCR assays targeting two different and conserved regions of the viral genome for the diagnosis of acute Hepatitis E virus (HEV) infection. Patients with acute hepatitis were prospectively recruited. In all, HEV-IgM antibodies were tested together with evaluation of HEV viraemia by two PCR assays (ORF3 and ORF1). The number of individuals exhibiting negative IgM antibody results but carrying viral RNA was calculated by each PCR assay. Four-hundred and seventy individuals were included, of whom 145 (30.8%) were diagnosed as having acute HEV. Of them, 122 (84.1%) exhibited HEV-IgM antibodies, and 81 (55.8%) had detectable viral RNA for at least one PCR. Using the ORF3 molecular assay, 70 (48.3%) individuals were identified with HEV infection. When the ORF1 molecular assay was applied, 49 (33.8%) individuals were identified. The ORF3 assay detected viral RNA in 32 patients not detected by the ORF1 assay. In contrast, the ORF1 assay could amplify viral RNA in 11 patients who were not detected by the ORF3 assay. The parallel use of two broad-range PCR assays significantly increased the performance of the molecular diagnosis of HEV.
dc.description.sponsorshipThis work was supported by Secretaria General de Investigacion, Desarrollo e Innovacion en Salud (PI-0287-2019) for grants for the financing of Investigacion, Desarrollo e Innovacion Biomedica y en Ciencias de la Salud en Andalucia; the Ministerio de Sanidad (RD12/0017/0012) integrated into the Plan Nacional de I + D + I and co-financed by the ISCIII-Subdireccion General de Evaluacion and the Fondo Europeo de Desarrollo Regional (FEDER); the Fundacion para la Investigacion en Salud (FIS) del Instituto Carlos III (Research Project grant numbers: PI19/00864, PI21/00793 and PI22/01098). Antonio Rivero-Juarez is the recipient of a Miguel Servet Research Contract by the Ministerio de Ciencia, Promocion y Universidades of Spain (CP18/00111). Mario Frias is the recipient of a Sara Borrell Research Contract program by the Ministerio de Ciencia, Promocion y Universidades of Spain (CD18/00091). AR is the beneficiary of Contratos para la intensificacion de la actividad investigadora en el Sistema Nacional de Salud by the Ministerio de Ciencia, Promocion y Universidades of Spain (INT20-00028). Javier Caballero Gomez is supported by the CIBER-Consorcio Centro de Investigacion Biomedica en Red-(CB21/13/00083), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion and Union Europea-NextGenerationEU.
dc.languageeng
dc.rightsAttribution 4.0 International (CC BY 4.0)*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshHumans *
dc.subject.meshHepatitis E virus *
dc.subject.meshHepatitis E *
dc.subject.meshHepatitis Antibodies *
dc.subject.meshImmunoglobulin M *
dc.subject.meshRNA, Viral *
dc.titleOptimization of the molecular diagnosis of the acute hepatitis E virus infection
dc.typeArtigo
dc.authorsophosLopez-Lopez, P.; Frias, M.; Perez-Jimenez, A.B.; Freyre-Carrillo, C.; Pineda, J.A.; Aguilera, A.; Fuentes, A.; Alados, J.C.; Reina, G.; Ramirez-Arellano, E.; Viciana, I.; Mesquita, J.; Caballero-Gomez, J.; Rivero-Juarez, A.; Rivero, A.
dc.identifier.doi10.1111/1751-7915.14247
dc.identifier.sophos6433d2afe8f2fa0e62f2b7e5
dc.issue.number6
dc.journal.titleMicrobial Biotechnology*
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.) - Complexo Hospitalario Universitario de Santiago::Microbioloxía
dc.page.initial1325
dc.page.final1332
dc.relation.projectIDSecretaria General de Investigacion, Desarrollo e Innovacion en Salud [PI-0287-2019]
dc.relation.projectIDMinisterio de Sanidad [RD12/0017/0012)]
dc.relation.projectIDISCIII-Subdireccion General de Evaluacion
dc.relation.projectIDFondo Europeo de Desarrollo Regional (FEDER)
dc.relation.projectIDFundacion para la Investigacion en Salud (FIS) del Instituto Carlos III [PI19/00864, PI21/00793, PI22/01098]
dc.relation.projectIDMinisterio de Ciencia, Promocion y Universidades of Spain [CP18/00111, CD18/00091, INT20-00028]
dc.relation.projectIDCIBER-Consorcio Centro de Investigacion Biomedica en Red [CB21/13/00083]
dc.relation.projectIDInstituto de Salud Carlos III
dc.relation.projectIDMinisterio de Ciencia e Innovacion
dc.relation.projectIDUnion Europea-NextGenerationEU
dc.relation.publisherversionhttps://doi.org/10.1111/1751-7915.14247
dc.rights.accessRightsopenAccess*
dc.subject.keywordAS Santiago
dc.subject.keywordCHUS
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo Original
dc.volume.number16


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution 4.0 International (CC BY 4.0)
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International (CC BY 4.0)